Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment

This study tests a combination of two drugs — cadonilimab (an immunotherapy) and anlotinib (a targeted therapy) — for people with advanced soft tissue sarcoma (a cancer of the muscles, fat, or connective tissue) that has stopped responding to standard chemotherapy. **You may be eligible if...** - You are between 18 and 70 years old - You have advanced or inoperable soft tissue sarcoma confirmed by biopsy - You have already tried at least one chemotherapy regimen (including an anthracycline drug) and your cancer has progressed - You have at least one tumor that can be measured on a scan - Your general health (ECOG score) is 0 or 1 - Your blood counts and organ function meet the required levels **You may NOT be eligible if...** - You have previously received immunotherapy (such as anti-PD-1 or anti-PD-L1 drugs) - You have an active autoimmune disease requiring treatment - You are currently taking immune-suppressing drugs - You have active hepatitis B or C, or HIV - You had a stroke, heart attack, or serious clotting event in the last 6 months - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.